BioScrip (NASDAQ:BIOS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
A number of other brokerages have also commented on BIOS. Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. SunTrust Banks set a $4.00 price target on BioScrip and gave the company a “buy” rating in a report on Thursday, December 21st. Finally, ValuEngine upgraded BioScrip from a “sell” rating to a “hold” rating in a report on Thursday, November 30th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $3.63.
Shares of BioScrip (NASDAQ:BIOS) traded down $0.04 during trading on Friday, hitting $2.97. The stock had a trading volume of 1,807,488 shares, compared to its average volume of 872,416. The company has a market capitalization of $373.69, a price-to-earnings ratio of -4.79 and a beta of 0.19. BioScrip has a 12 month low of $1.35 and a 12 month high of $3.39. The company has a current ratio of 1.91, a quick ratio of 1.60 and a debt-to-equity ratio of -6.11.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/10/bioscrip-bios-raised-to-buy-at-bidaskclub.html.
BioScrip Company Profile
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.